Collecting Duct Carcinoma of the Kidney: A Clinicopathological Study Of 9 Cases

Michaël Peyromaure(Hôpital Cochin), Stéphane Oudard(Assistance Publique – Hôpitaux de Paris), Annick Vieillefond(Hôpital Cochin), B Debré(Hôpital Cochin), Florian Scotté(Université Paris-Saclay), Nicolas Thiounn(Hôpital Cochin)
The Journal of Urology
October 1, 2003
10.1097/01.ju.0000086616.40603.ad
Cited by 94

Related Papers

Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2017|1.4k
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2021|645
ctDNA guiding adjuvant immunotherapy in urothelial carcinoma
|Nature|2021|603
Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial
|The Lancet Oncology|2021|411
Systemic anticancer therapy-induced peripheral and central neurotoxicity: ESMO–EONS–EANO Clinical Practice Guidelines for diagnosis, prevention, treatment and follow-up
|Annals of Oncology|2020|319